A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Active, not recruiting · Phase 1, Phase 2 · NCT06644768
Conditions: Non-small Cell Lung Cancer, Lung Cancer
At a glance
- Research payments reported, 2025
- $630,558
- U.S. investigators named
- 8
- Sites paid
- 13
- Planned or actual enrollment
- 137
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- valemetostat tosylate (drug), pembrolizumab (drug)
- Dates
- Started 2024-10-30; completion 2030-04-30
- Results posted
- Not yet
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
From ClinicalTrials.gov, last updated 2026-07-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $630,558 in research payments for this study in 2025 (617 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ghassan Al-jazayrly, M.D. Hematology & Oncology · Los Angeles, CA
- Lyudmila A. Bazhenova, M.D. Hematology & Oncology · San Diego, CA
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Chintan C. Gandhi, M.D. Hematology & Oncology · Tamarac, FL
- Christopher C. Croot, MD Hematology & Oncology · Pikeville, KY
- Zhonglin Hao, MD, PHD Medical Oncology · Lexington, KY
- Haiying Cheng, M.D. Internal Medicine · Bronx, NY
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Valkyrie Clinical Trials $237,652
- Thomas Jefferson University Hospital, PA $99,433
- University of Kentucky Research Foundation $85,248
- Biomedical Research Alliance of New York LLC $71,227
- The Regents of the University of California $52,452
- Brcr Global $43,974
- Virginia Cancer Specialists Fairfax $31,790
- Johns Hopkins Hospital, the, MD $1,702
- UK Markey Cancer Center $1,432
- Pikeville Medical Center, KY $1,432
- UC San Diego Moores Cancer Center $1,432
- California Research Institute $1,401
- UK Healthcare Markey Cancer Center $1,382
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.